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Hepatitis E virus (HEV) is the etiological agent for viral hepatitis type E, which is a major problem in the
developing world. Because HEV cannot be cultured in vitro, very little information exists on the mechanisms
of HEV gene expression and genome replication. HEV is a positive-strand RNA virus with three potential open
reading frames (ORFs), one of which (ORF2) is postulated to encode the major viral capsid protein (pORF2).
We earlier showed (S. Jameel, M. Zafrullah, M. H. Ozdener, and S. K. Panda, J. Virol. 70:207–216, 1996)
pORF2 to be a ;88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum
(ER)-directing signal at its N terminus. Treatment with the drugs brefeldin A and monensin suggest that the
protein may accumulate within the ER. Based on mutational analysis, we demonstrate Asn-310 to be the major
site of N-glycan addition. In COS-1 cell expression and in vitro translation experiments, we confirm the
ER-translocating nature of the pORF2 N-terminal hydrophobic sequence and show that the protein is co-
translationally, but not posttranslationally, translocated across the ER membrane. Earlier, we had also
demonstrated cell surface localization of a fraction of the COS-1 cell-expressed pORF2. Using glycosylation-
and translocation-defective mutants of pORF2, we now show that while transit of pORF2 into the ER is
necessary for its cell surface expression, glycosylation of the protein is not required for such localization. These
results may offer clues to the mechanisms of gene expression and capsid assembly in HEV.
Hepatitis E virus (HEV) is a human pathogen prevalent in
much of the developing world, where it causes sporadic and
epidemic forms of acute viral hepatitis (3, 11, 26, 41). The
disease has also been observed in parts of the world where
hepatitis is not endemic (43), mostly in relation to travel to
areas of endemicity but rarely without being associated with
another known risk factor (32). The transmission of HEV is
feco-oral, with only human-to-human transfer recognized so
far (14). However, the recent discovery of a novel virus closely
related to HEV in domestic swine (16) suggests possible zoo-
notic reservoirs as well.
The viral genome has been cloned from multiple geograph-
ically distinct isolates and shows a high degree of sequence
conservation (1, 2, 8, 32, 36, 40). Based on sequence homology
and genome organization, HEV was earlier classified as a
hepevirus, a new genus in the family Calciviridae (17). It has
also been suggested that HEV may be a nonenveloped alpha-
like virus closely related to the rubella virus (13, 27). HEV is
now classified, on an interim basis, in a separate family, the
hepatitis E-like viruses (9). Phylogenetic grouping suggests
that at least three closely related variants of HEV have been
identified. These include the US-1 strain (32) and the swine
HEV (16), the most variant Mexican strain (8), and another
group comprising the highly homologous isolates from Burma
(36), China (1, 2), India (24), and Pakistan (39).
The ;7.5-kb positive-sense RNA genome contains three
open reading frames (ORFs), designated ORF1, ORF2, and
ORF3 (36). Though no experimental data are available, based
on homology to other positive-sense RNA viruses, ORF1 is
postulated to encode the HEV nonstructural polyprotein (13).
Whether this polyprotein is processed is unknown, but it car-
ries domains found in viral methyltransferases, papain-like cys-
teine proteases, RNA helicases, and RNA-dependent RNA
polymerases (13). The remaining ORFs are found in the struc-
tural portion of the genome, with ORF2 postulated to encode
the viral capsid protein (pORF2) and ORF3 postulated to
code for a small protein (pORF3) whose function is as yet
undefined (36).
In the absence of an in vitro culture system, little informa-
tion is available on the mechanisms of HEV genome replica-
tion, protein expression, and processing. We have used a sub-
genomic expression strategy to study the properties and
interactions of the HEV ORF2 and ORF3 proteins (10, 44).
pORF3 expressed in animal cells was found to be a cytoskel-
eton-associated phosphoprotein which appears to be phos-
phorylated by the cellular mitogen-activated protein kinase.
Similar expression analysis of pORF2 showed it to be an 88-
kDa glycoprotein which is expressed intracellularly as well as
on the cell surface and has the potential to form homodimers
(10). Based on pulse-chase analysis, tunicamycin inhibition,
and endoglycosidase sensitivity, we suggested that pORF2 is
cotranslationally translocated via its N-terminal signal se-
quence into the endoplasmic reticulum (ER) where the signal
is processed. We further suggested that the protein may be
glycosylated in the ER at asparagine residues in one or more of
the three possible N-linked glycosylation sites showing the
Asn-X-Ser/Thr (N-X-S/T) sequence (10).
Using mutational analysis, we now conclusively demonstrate
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the presence of an ER-translocating signal sequence at the N
terminus of pORF2. We also show that while all three aspar-
agine residues in the N-X-S/T consensus are modified, Asn-310
is the major site of glycosylation. In vivo and in vitro assays
suggest that pORF2 is cotranslationally translocated across the
ER membrane. Localization studies suggest that while glyco-
sylation of pORF2 is the result of its transit through the ER, it
has no bearing on the cell surface expression of pORF2. These
results and their implications for HEV capsid assembly are
discussed.
MATERIALS AND METHODS
Vectors and mutagenesis. The expression vector pSG-ORF2 has been de-
scribed earlier (10). The ORF2[D2-34] mutant was generated by using an oligo-
nucleotide reconstruction approach. Plasmid pSG-ORF2 was digested with
BstEII and BamHI to obtain an ORF2 fragment lacking 127 bp at its 59 end (A
base in ATG start codon considered as position 1). The oligonucleotides used for
reconstruction were 35F, CTAGATGGGCGGTTCCGGCGGTGGTTTCTG
GG and 35R, GTCACCCCAGAAACCACCGCCGGAACCGCCTAC.
The annealed double-stranded oligonucleotide carried XbaI and BstEII sites at
its 59 and 39 ends, respectively, and reconstructed ORF2 without the coding
sequences for amino acids 2 to 34. The mutant gene was cloned in XbaI- and
BamHI-digested plasmid pBSK(1) (Stratagene, GmbH) and verified by dideoxy
sequencing. Subsequently, ORF2[D2-34] was cloned as a NotI-XhoI fragment in
plasmid pMT3 (35) and from there as a PstI-BamHI fragment in plasmid pSGI
(10). This resulted in plasmid pSG-ORF2[D2-34].
For site-directed mutagenesis, HEV ORF2 was cloned in plasmid pALTER-1
(Promega, Madison, Wis.) as a PstI-BamHI fragment, and mutagenesis was
carried out by published methods (42). The oligonucleotides used for mutagen-
esis were as follows, with lowercase letters indicating changed bases for the
Asn3Ala mutation at amino acid position 137, 310, or 562 in the ORF2 protein:
2-137, GATGTTGATAGGgcGTACTGCCG; 2-310, GGGGGTAAGGgcGCG
AAACTCA; and 2-562, TGCAGTGGTGgcGTAATTATAAGG. All single-site
mutants were verified by dideoxy sequencing by using primers specific for the
ORF2 sequence. The dual- and triple-site mutants were reconstructed in the
pALTER-1 background by using convenient restriction sites. The
ORF2[137,310] mutant was generated by cloning a 1.3-kb EcoRI fragment from
plasmid pALT-ORF2[310] into EcoRI-digested pALT-ORF2[137]. The other
mutants were generated by cloning a 1-kb SpeI-BamHI fragment from plasmid
pALT-ORF2[562] into SpeI-BamHI-digested pALT-ORF2[137] to yield ORF2
[137,562], by cloning the fragment into SpeI-BamHI-digested pALT-ORF2[310]
to yield ORF2[310,562], and by cloning the fragment into SpeI-BamHI-digested
pALT-ORF2[137,310] to yield the triple mutant ORF2[137,310,562]. All the
mutant ORF2 genes were moved as PstI-BamHI fragments into PstI-BamHI-
digested expression vector pSGI.
Transfection and labeling of cultured cells. COS-1 cells were maintained and
transfected with lipofectin (GIBCO-BRL) as described earlier (10). Metabolic
labeling of cells, treatment of cells with tunicamycin, preparation and immuno-
precipitation of cell lysates, and endoglycosidase H digestions were also carried
out as described earlier (10).
Treatment of cells with brefeldin A (BfA) and monensin were carried out
essentially as described elsewhere (28). Briefly, 40 h posttransfection, cells were
incubated in Dulbecco’s modified Eagle medium (DMEM) lacking cysteine and
methionine for 1 h, followed by labeling each 60-mm-diameter plate of cells with
200 mCi of [35S]-Promix (Amersham)/ml for 30 min. After removal of the label,
cells were further incubated in chase medium containing excess cysteine and
methionine (complete DMEM) for another 3 h. BfA and monensin, when used,
were present at the appropriate concentrations during the prelabeling, labeling,
and chase periods. Steady-state labeling of transfected cells was done for 4 h as
described earlier (10), with BfA present during the prelabeling and labeling
periods.
Preparation of microsomes. The preparation of microsomal membranes and
protease protection of translocated pORF2 was carried out essentially as de-
scribed previously (25). Forty hours posttransfection, COS-1 cells were labeled
with [35S]promix for 4 h. The cells were washed twice with cold Tris-buffered
saline (TBS; 50 mM Tris-HCl [pH 7.5], 150 mM NaCl), incubated in 0.13 TBS
(0.45 ml per 60-mm-diameter plate) for 15 min on ice, and the swollen cells were
disrupted by 20 strokes of Dounce homogenization. After the debris was re-
moved at 2,500 rpm and 4°C for 20 min, the supernatant was made to 13 TBS
by using 103 TBS. One milliliter of this supernatant was overlaid on a 2.7-ml
cushion of 250 mM sucrose in TBS and centrifuged at 37,000 rpm and 4°C for 30
min in a SW60 rotor (Beckman). The pellet, comprising the microsomal fraction,
was resuspended in 0.1 ml of TBS containing 2 mM tetracaine and 2 mM CaCl2
(per SW60 tube or two 60-mm-diameter plate of cells). For protease protection
studies, the microsomal fraction was divided into three equal aliquots and
treated as follows: (i) no additions, (ii) 25 mg of trypsin/ml, and (iii) 25 mg of
trypsin/ml and 0.5% Nonidet P-40 (NP-40). After incubation on ice for 60 min,
the reaction mixtures were adjusted to 40 mg of aprotinin/ml and 2 mM phenyl-
methylsulfonyl fluoride (PMSF) and incubated on ice for another 20 min. Sub-
sequently, all reaction mixtures were adjusted to 13 radioimmunoprecipitation
assay (RIPA) buffer and immunoprecipitated with antibodies to pORF2 as
described earlier (10).
In vitro translation and translocation. In vitro transcription and translation
was carried out by using a coupled transcription-translation system (TNT cou-
pled reticulocyte lysate system; Promega) according to the manufacturer’s in-
structions. In a 25-ml reaction mixture, 0.5 mg of circular plasmid DNA was
transcribed with T7 RNA polymerase and translated by using reticulocyte lysate
and 20 mCi of either [35S]-Promix (Amersham) [35S]methionine (BRIT, Mum-
bai, India). Canine pancreatic membranes (Promega), when present, were used
at an optimal amount determined experimentally.
To assay for translocation of in vitro-synthesized proteins across microsomal
membranes, trypsin protection was carried out essentially as described above.
Following protein synthesis at 30°C for 90 min, the reaction mixtures were chilled
on ice, and 20 ml of the sample loaded on a 1-ml cushion of 250 mM sucrose in
TBS. The tubes were centrifuged at 11,400 rpm for 30 min in a refrigerated
microfuge (Biofuge 17RS; Heraeus GmbH). The supernatant was discarded, and
the pellet was resuspended in 40 ml of TBS containing 2 mM tetracaine and 2
mM CaCl2. The resuspended pellet was divided into three equal aliquots and
treated with trypsin and NP-40 as described above for the COS-1 cell microsomal
fraction. Following proteolysis, the reaction was terminated with aprotinin and
PMSF, an equal volume of 23 sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) loading dye was added, and the samples were boiled
and subjected to SDS-PAGE.
Alternatively, protease digestion was also carried out without prior separation
of the canine pancreatic membranes after the translocation period (23). Follow-
ing protein synthesis at 30°C for 90 min, in the absence or presence of mem-
branes, the reaction mixtures were quenched with 100 mg of cycloheximide/ml
and 200 mM methionine and kept at 30°C for another 60 min. The reactions were
then chilled on ice, adjusted to 3 mM in tetracaine and 10 mM in CaCl2, and
divided into three equal aliquots. These were treated on ice for 1 h as follows: (i)
no additions, (ii) 250 mg of trypsin/ml, and (iii) 250 mg of trypsin/ml and 0.7%
Triton X-100. The proteolytic reaction was terminated by transferring it, with a
tip dipped in 200 mM PMSF, to an equal volume of boiling 23 SDS-PAGE
loading dye. The samples were boiled and subjected to SDS-PAGE.
For posttranslational translocation, in vitro-coupled transcription-translation
was carried out as described above at 30°C for 90 min in the absence or presence
of canine pancreatic membranes. Cycloheximide was added to 100 mg/ml, and
the reaction mixtures were incubated at 30°C for 15 min. To the reaction mix-
tures 1 or 2 ml of canine pancreatic membranes was added and incubated at 30°C
for another 30 min. Trypsin protection was then carried out with either of the two
methods described above for cotranslational translocation.
Immunofluorescence. COS-1 cells were grown on autoclaved glass coverslips
(18 mm diameter) placed individually inside the wells of a 12-well tissue culture
plate and transfected with the appropriate plasmids. Forty hours posttransfec-
tion, cells were washed three times with phosphate-buffered saline (PBS), fixed
with 4% paraformaldehyde for 30 min at room temperature, and again washed
with PBS as earlier. The fixed cells were then incubated for 2 h at 37°C in a humid
chamber with rabbit anti-pORF2 (1:200 dilution in 0.5% bovine serum albumin
[BSA]–PBS), either in the absence or presence of 0.1% saponin. The antibody
was earlier preadsorbed on fixed and untransfected COS-1 cells. Following three
washes of 5 min each in PBS, the cells were incubated as described above for 1 h
with anti-rabbit immunoglobulin G (IgG)–fluorescein isothiocyanate (FITC)
conjugate (1:200 dilution in 0.5% BSA–PBS; Sigma). The cells were washed with
PBS as described above, and the coverslips were mounted on glass slides with a
drop of 20% glycerol. Viewing and photography were carried out on a fluores-
cence microscope (Wild Leitz, GmbH).
RESULTS
Domain analysis of pORF2. The 660-amino-acid protein
encoded by ORF2 of HEV was analyzed for the presence of
membrane-translocating signals and N-linked glycosylation
sites. The hydropathy profile of pORF2 showed the presence
of a highly hydrophobic stretch, rich in leucines, at its N ter-
minus, followed by turn-inducing and positively charged amino
acids. Such an N-terminal stretch makes up the export signal
sequence generally found in proteins that are translocated
across cellular membranes (31). A search for potential N-
linked glycosylation sites with the consensus N-X-S/T (X, any
amino acid except Pro) revealed the presence of three such
sites within pORF2, Asn-137, Asn-310, and Asn-562. These
features were found in the deduced amino acid sequences of
ORF2 from all isolates of HEV sequenced so far and are
shown in Fig. 1A. Various mutants used in this study are
schematically illustrated in Fig. 1B, and the details of their
construction are presented in Materials and Methods. Essen-
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tially, these included a deletion of the N-terminal putative
signal sequence and Asn3Ala mutations at amino acid posi-
tions 137, 310, and 562, either alone or in different combinations.
pORF2 is glycosylated in the ER. The complete susceptibil-
ity of glycosylated pORF2 (gpORF2) to endoglycosidase H
(endo H) (10) suggested that it carried high-mannose residues,
a modification that takes place within the ER (38). To further
analyze this, we used the drugs brefeldin A and monensin.
When the protein was transiently expressed in COS-1 cells, two
forms, pORF2 and its glycosylated version, gpORF2, were
observed, as earlier. The gpORF2 was susceptible to tunica-
mycin and endo H, both treatments reducing it to pORF2 (Fig.
2A, lanes 1 to 3). In a pulse-chase experiment, an alternatively
modified and slower-migrating form of gpORF2 was observed
upon treatment with 10 mg of BfA/ml (Fig. 2A, lanes 4 to 6).
Some of this modified form of gpORF2 was endo H resistant,
FIG. 1. ORF2 features and mutants. (A) The 660-amino-acid protein (pORF2) encoded by HEV ORF2 is shown schematically, with two major regions: the extreme
N terminus, containing the putative signal sequence (filled), and the basic highly N-terminal half of the protein, containing about 10% arginine residues (dotted). The
extreme N-terminal region is expanded to show three domains characteristic of eukaryotic signal sequences, the hydrophobic core domain, a region containing
turn-inducing amino acids, and a positively charged domain (1). The positions of three potential N-linked glycosylation sites (N-X-S/T) are shown at amino acid
residues 137, 310, and 562 in the primary sequence of pORF2. (B) Various mutants used in this study are shown schematically. The D2-34 mutant carries a 59-end
deletion in ORF2 corresponding to amino acids 2 to 34 in the polypeptide sequence. The glycosylation mutants with Asn3Ala changes at the indicated positions are
shown (F). The nomenclature corresponds to the amino acid position(s) changed in that particular mutant.
FIG. 2. Effects of brefeldin A and monensin on pORF2 expression. (A) COS-1 cells transfected with pSG-ORF2 were pulse-labeled with [35S]promix for 30 min,
followed by a 3-h chase in complete DMEM. The cells were left untreated (lanes 1 and 3) or treated with 10 mg of brefeldin A (lanes 4 to 6)/ml, 5 mM monensin (lanes
7 to 9), or 10 mg of tunicamycin (lanes 2, 5, and 8)/ml during the prelabeling, pulse-labeling, and chase periods. Cell lysates were prepared, and the polypeptides were
immunoprecipitated with a rabbit anti-pORF2 antiserum. Washed immunoprecipitates were subjected to mock treatment (lanes 1, 2, 4, 5, 7, and 8) or Endo H digestion
(lanes 3, 6, and 9), and the polypeptides were analyzed on an SDS–7.5% polyacrylamide gel, followed by fluorography. Various treatments (1), the positions of gpORF2
and pORF2, and molecular size markers are indicated. (B) COS-1 cells transfected with pSG-ORF2 (lanes 1 to 4) or pSG-ORF2[D2-34] (lanes 6 to 9) were labeled
with [35S]promix for 4 h in the absence (lanes 1, 2, 6, and 7) or presence (lanes 3, 4, 8, and 9) of 2.5 mg of brefeldin/ml. Following immunoprecipitation, the polypeptides
in the precipitates were mock treated (lanes 1, 3, 5, and 7) or digested with Endo H (lanes 2, 4, 6, and 8) and analyzed on an SDS–7.5% polyacrylamide gel, followed
by fluorography. The positions of gpORF2 and pORF2 are indicated. Only molecular size markers corresponding to 97.4 and 66 kDa are shown.
4076 ZAFRULLAH ET AL. J. VIROL.
as apparent from the heterogeneous forms present above the
pORF2 band. Such an effect was also observed with BfA con-
centrations as low as 1 mg/ml (data not shown). Used similarly,
5 mM monensin showed no effect on pORF2 glycosylation
(Fig. 2A, lanes 7 to 9). This was also true with monensin
concentrations as high as 20 mM (data not shown). The
gpORF2 form, either in the absence of the drugs or in the
presence of monensin, remained completely susceptible to tu-
nicamycin and endo H treatments. These experiments con-
firmed our earlier observations and, as discussed later, sug-
gested that the ER is the major site of intracellular
accumulation of gpORF2.
Treatment with BfA also resulted in significantly reduced
levels of the nonglycosylated pORF2 (Fig. 2A, lanes 4 to 6). A
labeling experiment was carried out in which steady-state ex-
pression levels of pORF2 or its N-terminal deletion mutant
pORF2[D2-34] were estimated. As shown in Fig. 2B, steady-
state levels of pORF2 and gpORF2 were significantly reduced
in BfA-treated cells. Again, alternately modified and partially
endo H-resistant forms of gpORF2 were observed (lanes 3 and
4). While BfA showed a generalized toxic effect on pORF2
expression, taken together with the pulse-chase results (Fig.
2A), it appeared to increase turnover of the ORF2 protein.
Asn-310 is the primary site of glycosylation. To determine
which of the three potential N-linked glycosylation sites are
modified in pORF2, we constructed a number of site-directed
mutants in which one or more of the asparagine residue(s) in
the N-X-S/T sequon were changed to alanine(s). COS-1 cells
were transiently transfected with expression vectors containing
either wild-type or mutant ORF2. The cells were metabolically
labeled with [35S]methionine-cysteine in the absence or pres-
ence of tunicamycin, cell lysates were subjected to immuno-
precipitation, and the proteins were analyzed by SDS-PAGE.
The results are presented in Fig. 3. The single-site mutants
ORF2[137], ORF2[310], and ORF2[562] all showed the pres-
ence of gpORF2 (lanes 3 to 8). The dual-site mutants
ORF2[137,310] and [310,562], i.e., those that include Asn-310
along with either of the other two sites, were found to express
pORF2, but the protein was not glycosylated (lanes 12 and 16).
Alternatively, the protein may carry only minimal glycosyla-
tion, such that the nonglycosylated and glycosylated forms re-
main unresolvable on the gel. In contrast, the dual-site mutant
ORF2[137,562], in which the Asn-310 residue was unchanged,
expressed the pORF2 as well as gpORF2 forms of the protein
(lane 14). However, the mobility of mutant gpORF2 was
higher than that of wild-type gpORF2 (compare lanes 1 and 10
to lanes 3, 5, 7, and 14). As expected, the triple mutant
ORF2[137,310,562] expressed only the nonglycosylated form
of the protein (lane 18). Verification that the slower-moving
forms in all the mutants were indeed gpORF2 was ascertained
through tunicamycin inhibition experiments. These results
strongly indicate that Asn-310 is the major, though not the
only, site of glycosylation on the ORF2-encoded protein.
pORF2 carries an N-terminal signal sequence. To deter-
mine if the N-terminal region of pORF2 carried a functional
signal sequence, a deletion mutant, ORF2[D2-34], was made in
which sequences corresponding to residues 2 to 34 of pORF2
were deleted. This included the hydrophobic leucine-rich re-
gion as well as the charged arginine-rich region following it
(Fig. 1A). This mutant ORF2 construct was also transfected
into COS-1 cells and was found to express only the nonglyco-
sylated form of the protein (Fig. 3, lanes 20 and 21). The
presence of all three of the potential glycosylation sites in this
deletion mutant indicated that the N-terminal region of
pORF2 carried a signal sequence which directed the protein
into the ER for glycosylation.
To further ascertain the ER-directing function of this signal
sequence, in vivo and in vitro translocation assays were carried
out. COS-1 cells transiently transfected with wild-type ORF2
or ORF2[D2-34] expression vectors were metabolically labeled
with [35S]methionine-cysteine and subjected to subcellular
fractionation. The microsomal fraction was prepared as de-
scribed in Materials and Methods. The washed microsomes
were then subjected to digestion with trypsin in the absence or
FIG. 3. Expression and glycosylation of mutant pORF2 proteins. COS-1 cells transfected with pSG-ORF2 (lanes 1, 2, 10, and 11), pSG-ORF2[Asn3Ala mutants]
(lanes 3 to 8 and 12 to 19), or pSG-ORF2[D2-34] (lanes 20 and 21) were labeled with [35S]promix for 4 h. Tunicamycin (10 mg/ml) was absent (2) or present (1) during
the prelabeling and labeling periods as indicated. After immunoprecipitation, the polypeptides were analyzed on a SDS–7.5% polyacrylamide gel, followed by
fluorography. The positions of gpORF2 and pORF2 are indicated. Only molecular size markers corresponding to 97.4 and 66 kDa are shown (lanes 9 and 22). WT,
wild type; TM, tunicamycin.
FIG. 4. Microsomal localization of pORF2. COS-1 cells transfected with
pSG-ORF2 were labeled with [35S]promix for 4 h and used to prepare the
microsomal fraction as described in Materials and Methods. The microsomal
fraction was then incubated in the absence (2) or presence (1) of 25 mg of
trypsin/ml and/or 0.5% NP-40, on ice for 60 min. Following immunoprecipita-
tion, the polypeptides were analyzed on an SDS–10% polyacrylamide gel, fol-
lowed by fluorography. The positions of gpORF2 and pORF2 are indicated.
Molecular size markers are shown (lane 1).
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presence of a nonionic detergent (NP-40). The wild-type
pORF2/gpORF2 (Fig. 4, lane 2) was found in the microsomal
fraction. The pORF2[D2-34] mutant was not found in the
microsomal fraction but was present in the cytosolic fraction
(data not shown). Further, wild-type pORF2/gpORF2 was re-
sistant to trypsin digestion in the absence (lane 3) but not in
the presence of NP-40 (lane 4). The protection from trypsin
was, however, not quantitative. This can be explained by the
protection of only fully translocated forms, while those in the
process of being translocated would remain sensitive to trypsin.
A cellular protein of ;46 kDa was found to cross-react with
anti-pORF2 (lanes 2 and 3). The possibility that this repre-
sented a cross-reacting polypeptide associated with the micro-
somal fraction is suggested by its presence in immunoprecipi-
tates of mock-transfected cells as well (data not shown).
The translocation of pORF2, followed by trypsin resistance,
was also carried out in vitro. By using a coupled transcription-
translation system, pORF2/gpORF2 was synthesized in the
absence or presence of added microsomal membranes. The
wild-type protein (Fig. 5A), but not the D2-34 mutant protein
(Fig. 5B), was found to be resistant to trypsin when synthesized
in the presence of membranes. In the absence of membranes,
both proteins were susceptible to trypsin. The triple Asn mu-
tant protein, pORF2[137,310,562], was also resistant to trypsin
only when synthesized in the presence of membranes (Fig. 5C).
A few discrete bands smaller than the full-length polypeptide
were observed in the trypsin-treated pORF2[D2-34] mutant
synthesized in the presence of membranes (Fig. 5B, lanes 6 and
7). These appear identical to the bands observed when either
pORF2 (Fig. 5A, lanes 2 and 3) or pORF2[D2-34] (Fig. 5B,
lanes 2 and 3), synthesized in the absence of membranes, was
treated with trypsin. This observation further reinforces the
lack of pORF2[D2-34] translocation across microsomal mem-
branes.
Taken together, the results presented in Fig. 4 and 5 con-
firmed that pORF2 carrying the N-terminal signal sequence is
cotranslationally translocated across the microsomal mem-
brane.
Experiments were carried out to distinguish between co-
translational and posttranslational translocation of pORF2. To
assess any possible posttranslational translocation, the transla-
tion reaction was terminated with cycloheximide and in vitro-
synthesized proteins were incubated with microsomal mem-
branes. The membranes were pelleted through a cushion of
250 mM sucrose–TBS, and translocation across these mem-
branes was assayed by resistance to trypsin. While pORF2
translated in the presence of membranes was protected from
trypsin (Fig. 6, lanes 2 to 5), pORF2 synthesized in the absence
of membranes was not protected from trypsin when transloca-
tion-competent microsomal membranes were added following
translation (Fig. 6, lanes 7 to 10). Further, no gpORF2 band
was observed when in vitro-translated pORF2 was incubated
with the canine pancreatic membranes subsequent to its syn-
thesis. These results showed that pORF2 can translocate
across microsomal membranes in a cotranslational manner but
not in a post-translational manner.
pORF2 translocation, but not glycosylation, is required for
its cell surface localization. Previous results showed that a
fraction of pORF2/gpORF2 is expressed on the cell surface.
However, it was not clear whether glycosylation of pORF2 into
its gpORF2 form was a prerequisite for such cell surface ex-
pression. Through indirect immunofluorescence, we analyzed
the cell surface and intracellular localization of the wild-type
and mutant forms of pORF2. While the wild-type (Fig. 7A and
B) and the glycosylation-defective mutant pORF2[137,310,
562] (Fig. 7E and F) proteins showed intracellular as well as
cell surface localization, the signal sequence-deficient pORF2
[D2-34] form of the protein localized intracellularly, but not to
the cell surface (Fig. 7C and D). This result suggested that
while pORF2 glycosylation is not required, its translocation to
the ER and entry into the secretory network are prerequisites
for its cell surface localization.
DISCUSSION
Comparative analyses of homologous domains and consen-
sus sequences in proteins provide good starting points for
understanding structural and functional properties of new pro-
teins. Analysis of the HEV putative major capsid protein,
FIG. 5. In vitro synthesis and translocation of pORF2 and its mutants. Cou-
pled transcription-translation reactions were carried out by the TNT T7 system
(Promega) programmed with plasmid pSG-ORF2 (A), pSG-ORF2[D2-34] (B),
or pSG-ORF2[137,310,562] (C). Canine pancreatic membranes were absent
(lanes 1 to 3) or present (lanes 4 to 7) during the in vitro reaction. Subsequently,
each reaction mix was divided into three parts and either mock treated (lanes 1
and 5) or treated directly with 250 mg of trypsin/ml in the absence (lanes 2 and
6) or presence (lanes 3 and 7) of 0.7% Triton X-100. The protected polypeptides
were analyzed on an SDS–7.5% polyacrylamide gel, followed by fluorography.
Molecular size markers (lane 4) are shown as in Fig. 4. The positions of gpORF2,
pORF2, pORF2[D2-34], and pORF2[137,310,562] are indicated.
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pORF2, suggested that this protein may go through the cellu-
lar secretory pathway, undergoing modifications en route. Ear-
lier we showed that pORF2 carried N-linked glycans of the
high-mannose type and that the nascent protein underwent
processing subsequent to its synthesis (10). Here we provide
additional details of pORF2 glycosylation and processing.
N-linked oligosaccharides are synthesized as a core unit of
Glc3MangGlc-NAc2 attaching to asparagines at N-X-S/T se-
quences while the polypeptide chains are being translocated
across the ER membrane (4). The glycosylation pattern of a
glycoprotein reflects the cellular compartment through which
it has passed during its synthesis and processing. Our earlier
results suggested that pORF2 underwent glycosylation within
the ER (10). Here we have analyzed the effects of the drugs
brefeldin A and monensin on pORF2 glycosylation.
Brefeldin A is a fungal metabolite that disrupts intracellular
membrane traffic at the ER-Golgi junction (20), resulting in a
redistribution of Golgi enzymes into the ER. Since BfA col-
lapses Golgi enzymes into the ER, it is not surprising to find
some gpORF2 becoming endo H resistant, as observed in Fig.
2A and B. It was, however, surprising to find that wild-type
gpORF2 was completely sensitive to endo H. This seems to
indicate that the major site of intracellular accumulation of
gpORF2 is the ER. Similar observations have been made in
the case of rotavirus VP7 protein (19) and the spleen focus-
forming virus glycoprotein, gp55 (40). Monensin, a metabolite
of Streptomyces cinnamonensis, impairs Golgi function (21),
and in our studies, did not interfere with the glycosylation of
pORF2. This would be expected if most of the protein was not
leaving the ER. Alternatively, it may move directly from the
ER to the cell surface, as suggested for the hepatitis B virus M
protein (34). The data presented here, though persuasive, are
not sufficient for proving existence of the intracellular traffick-
ing pathway of the HEV ORF2 protein. However, the obser-
vations do suggest that the HEV capsid, or at least a precursor,
may assemble within the ER.
Tunicamycin and endoglycosidase digestion experiments
carried out earlier showed that pORF2 was N-glycosylated
(10). In its 660-amino-acid sequence, it contains three N-X-S/T
motifs which can act as potential acceptor sites. These sites are
conserved in the ORF2 sequences of all HEV isolates se-
quenced so far (1, 2, 8, 32, 36, 39), as well as in swine HEV
(16). To analyze which one of these potential site(s) was gly-
cosylated, we made site-directed mutants such that the aspar-
agine residues at positions 137, 310, and 562, within the pri-
mary amino acid sequence of pORF2, were individually
changed to alanines. The glycosylation pattern of these mu-
tants suggested that Asn-310 was the primary site of modifica-
tion though not the only one; the other two sites were also
utilized. However, since double mutants carrying the Asn-
3103Ala mutation along with either the Asn-137 or the Asn-
562 mutation failed to produce gpORF2, it appears that Asn-
310 is the major site of glycosylation. The inability of the
mutant protein pORF2[137,310,562] to undergo glycosylation
ruled out any more sites at which N-glycans can be added to
the protein.
Nascent polypeptides crossing the ER membrane are co-
translationally N-glycosylated at the N-X-S/T motif by the oli-
gosaccharide complex, which consists of several subunits (30)
and lies close to the protein translocation channel. There ap-
pears to be structural specificity with respect to glycosylation
efficiency in that the amino acids proline, aspartic acid, and
glutamic acid are not tolerated at the X position (33). Further,
statistical analysis of a wide range of N-glycosylated proteins
suggests that proline residues either at the X position or next
to the serine/threonine position greatly reduce the degree of
glycosylation (5). In this context, it is interesting that a proline
residue is present next to the 310N-L-T motif in the deduced
pORF2 sequences from all except the Mexican isolate of HEV;
yet, this appears to be the major glycosylation site within
pORF2. The low overall amounts of N-glycans added to
pORF2 may reflect this sequence constraint.
Secretory and plasma membrane proteins are targeted to the
ER membrane via their signal peptides, which are usually
located at the amino terminus of the nascent polypeptides (31).
Signal sequences increase the specific interaction of a protein
with its appropriate transport machinery. It is generally as-
sumed that signal sequences have highly degenerate primary
sequences but a common secondary structure or a similar dis-
tribution of charged and apolar residues (31). The signal pep-
tide consists of three regions, an amino-terminal polar region
of 2 to 40 amino acids, a central hydrophobic region of 7 to 20
amino acids, and a variable-length sequence containing turn-
inducing amino acids, followed by the signal peptidase cleav-
age site (31). A hydropathy plot of pORF2 and close exami-
nation of its amino-terminal sequence revealed the presence of
all these features. Taken together with our earlier pulse-chase
studies, showing processing of the nascent pORF2 polypeptide
(10), this suggested the presence of a functional ER-translo-
cating signal sequence at the amino terminus of pORF2.
A deletion mutant of ORF2 was constructed in which se-
quences corresponding to amino acids 2 to 34 were deleted.
This included all three regions of the putative signal sequence
mentioned above. Expressed in COS-1 cells, the mutant pro-
tein showed no glycosylation, even though all three of the
N-linked glycosylation sites were present.
The translocation of wild-type and mutant pORF2 polypep-
tides into microsomes was also studied by using resistance to
trypsin as an assay for translocation. In transfected COS-1 cells
a significant fraction of the wild-type protein was found within
isolated microsomes. The N-terminally-deleted pORF2[D2-34]
protein, however, was cytosolic in its subcellular localization.
In an in vitro translation system, the wild-type but not the
D2-34 mutant protein was sequestered within exogenously
added microsomes. The glycosylation-null triple-Asn mutant
protein, pORF2[137,310,562], which carried an intact N-termi-
FIG. 6. Co- and posttranslational translocation of pORF2. Plasmid pSG-
ORF2 was subjected to in vitro-coupled transcription-translation. Following co-
or posttranslational translocation of the in vitro-synthesized protein, as described
in Materials and Methods, the membranes were pelleted down through a 250
mM sucrose–TBS cushion, resuspended in TBS, and divided into three equal
aliquots. The aliquots were either mock treated (lanes 3 and 8) or treated with
25 mg trypsin/ml in the absence (lanes 4 and 9) or presence (lanes 5 and 10) of
0.5% NP-40. Input reactions, prior to membrane pelleting, are also shown (lanes
2 and 7). The positions of gpORF2 and pORF2 and the 97.4- and 66-kDa
markers (lanes 1 and 6) are indicated.
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FIG. 7. Cell surface and intracellular localization of pORF2 and its mutants. COS-1 cells transfected with pSG-ORF2 (A and B), pSG-ORF2[D2-34] (C and D),
or pSG-ORF2[137,310,562] (E and F) were fixed with 4% paraformaldehyde–PBS and stained with rabbit anti-pORF2, followed by the goat anti-rabbit IgG-FITC
conjugate. Antibody incubations were carried out in the absence (A, C, and E) or presence (B, D, and F) of 0.1% saponin for surface and intracellular staining,
respectively. The stained cells were mounted in 20% glycerol and viewed and photographed with a fluorescence microscope. Representative views are presented.
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nal signal sequence, also translocated to the ER and was pro-
tected from trypsin digestion.
The in vitro synthesis of wild-type and mutant forms of
pORF2, followed by a translocation assay with trypsin also
provided some insight into the folding of this protein. Being
rich in lysine and arginine residues, the protein has 59 possible
trypsin digestion sites, rarely resulting in peptides 50 amino
acids or longer. Yet, at least four distinct bands of about 40 to
60 kDa were observed upon tryptic digestion, suggesting ex-
tensive folding of the in vitro-synthesized polypeptide, result-
ing in the sequestration of a majority of trypsin-sensitive sites.
The N-terminally-deleted protein lacking the first 34 amino
acids, pORF2[D2-34], appeared to fold almost identically to
the wild-type pORF2, as was apparent from the major tryptic
fragments generated. Interestingly, when just three conserved
residues involved in the N-linked glycosylation of pORF2 were
changed, the mutant pORF2[137,310,562] became completely
sensitive to trypsin in the absence of microsomal membranes.
This observation is compatible with a drastically different fold-
ing of this mutant polypeptide.
Proteins are translocated across the ER membrane through
two distinct pathways, one dependent upon the signal recog-
nition particle (SRP) (29) and the other independent of it (6).
The targeting route depends largely upon the hydrophobicity
of the signal sequence present on the protein to be translo-
cated (22). Proteins with a hydrophobicity index (according to
Kyte-Doolittle) of 12.0 or less show SRP-independent trans-
location, while those with an index approaching 13.0 are SRP
dependent (22). An analysis of the pORF2 signal sequence
showed a hydrophobicity index of 13.0 for the core, suggesting
an SRP-dependent mode of translocation. This is further sup-
ported by experiments showing cotranslational but not post-
translational translocation of pORF2 in the presence of exog-
enously added microsomal membranes. SRP-dependent
translocation tends to be cotranslational (29), while the SRP-
independent translocation is posttranslational (22). It will be of
interest to determine if pORF2 interacts with components of
the SRP and resident ER proteins.
The localization of wild-type and mutant ORF2 proteins at
the cell surface was studied by indirect immunofluorescence of
the transfected cells. Since both wild-type and the glycosyla-
tion-null triple-Asn mutant but not the signal-deleted mutant
were found on the cell surface, the ER localization of pORF2
and its entry into the cellular secretory network are essential
prerequisites for cell surface localization of pORF2/gpORF2.
Glycosylation of pORF2 is not important for its appearance on
the cell surface.
What is the functional significance of pORF2 glycosylation?
It is not clear if the addition of N-glycans has any role to play
in viral capsid assembly or virus-host cell interactions. The
modification of pORF2 may occur simply because the protein
has accessible N-linked glycosylation sites and is translocated
to the ER, where the cellular machinery for such a modifica-
tion is available. However, trypsin sensitivity studies on wild-
type and mutant proteins, discussed above, suggest an impor-
tant structural role for pORF2 glycosylation. Further, the
pORF2 amino-terminal signal sequence and all three N-linked
glycosylation sites are universally found in all isolates of human
HEV as well as in the newly discovered swine HEV. Therefore,
it is likely that pORF2 glycosylation has a functional signifi-
cance as well. It is possible that all or part of the HEV capsid
assembles within the ER. N-linked oligosaccharides are known
to increase the solubility and stability of many proteins and
thus to help in their proper folding (7). That would be critical
for viral capsid assembly, since multiple identical subunits must
come together to form that structure.
While glycosylation of surface proteins is essential for the
assembly of enveloped viruses, little information exists about
the function of carbohydrates on the capsid protein(s) of non-
enveloped viruses. The rotavirus VP7 protein becomes resis-
tant to endo H upon brefeldin A treatment (19), and a com-
bination of tunicamycin and brefeldin A results in misfolding
and interdisulfide bond aggregation of the lumenal VP7 pro-
tein (18). Further, while glycosylated VP7 was found to inter-
act with protein disulfide isomerase, nonglycosylated VP7 did
not. This result is taken to mean that the major function of
carbohydrates on VP7 is to facilitate correct disulfide bond
formation and protein folding (18). It has also been proposed
that capsid glycosylation may render the virus more resistant to
the gastric environment (18). Similar roles may be proposed
for pORF2 glycosylation.
Following proper folding in the ER, N-glycans are also
known to play a role in biosynthetic traffic beyond the ER (4).
However, few studies have differentiated between the effects of
N-glycans on protein folding in the ER and their role in sub-
sequent transport to the plasma membrane. The requirements
for glycosylation appear to be more stringent for membrane
proteins than for secreted proteins. The cell surface expression
of very few plasma membrane proteins, such as pORF2 de-
scribed here, is unaltered by inhibition of glycosylation (4).
However, we need to examine pORF2 transport kinetics quan-
titatively through pulse-chase and cell fractionation studies to
be able to state this finding conclusively.
Another proposed role for N-glycans is sorting signals in
polarized cells. For example, erythropoietin, an apically se-
creted protein in MDCK cells, is discharged equally from the
apical and basolateral surfaces when its three N-glycosylation
sites are removed by mutagenesis (12). Even in nonpolarized
cells such as fibroblasts, the existence of two sorting pathways
analogous to the apical and basolateral routes in MDCK cells
is postulated (15). Because hepatocytes are polarized cells,
newly synthesized HEV particles may exit the cell preferen-
tially from one surface and N-glycosylation of pORF2 may be
a determinant for that selectivity. Clearly, a number of ques-
tions are unanswered; these will be the focus of our future
efforts.
While no in vitro culture system exists for HEV, a primary
infectivity system with hepatocytes from experimentally in-
fected nonhuman primates has recently become available (37).
It will be of interest to develop comparative data by such a
system for the expression and processing of HEV proteins.
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